7-5/2022/EU/WC-0542
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated:
09 DEC 2022

To,

M/s. Aurore Life Sciences Private Limited
Plot No. 180/2 & 3, Khazipally (V), Jinnaram (M)
Sangareddy – 502 319 , Telangana, India

SUB:- Written Confirmation of M/s. Aurore Life Sciences Private Limited, Plot No. 180/2 & 3, Khazipally (V), Jinnaram (M), Sangareddy – 502 319 , Telangana, India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your online application No. WC/FR/2022/2970 submitted to CDSCO, Hyderabad Zonal office and the recommendation received from DDC(I), Hyderabad Zonal office on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).

2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.

3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.

4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.

5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.

6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.

7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.

8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
01	02	09 DEC 2022	Three years from date of issue
02	01	09 DEC 2022	Three years from date of issue

Yours faithfully,

(Dr. V. G. Somani)
Drugs Controller General (India)

GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

CERTIFICATE NO. : **WC-0542**

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: **M/s. Aurore Life Sciences Privated Limited**
Plot No. 180/2 & 3, Khazipally (V), Jinnaram (M)
Sangareddy – 502 319 , Telangana, India

2. Manufacturer's licence number: TS/SGY/2021-75533, TS/SGY/2021-74501

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use

List of API(s):

As per Annexure-01 & Annexure-02

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU (= GMP of WHO/ICH Q7);

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.

Date of Inspection of the plant: 27.09.2021 & 28.09.2021

The Written Confirmation remains valid until: Three years from date of issue

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

Address of the issuing regulatory authority: **Central Drugs Standard Control Organisation**
FDA Bhawan, Kotla Road,
New Delhi- 110 002, India

Name and function of responsible person: Dr. V. G. Somani,
Drugs Controller General (India)

E-mail: dci@nic.in,
Telephone no.: +91-11-23236965
Fax no.: +91-11-23236973

Signature

Stamp of the authority and date

Central Drugs Standard Control Organization • Ministry of Health & Family Welfare, Govt. of India • सत्यमेव जयते

09 DEC 2022

Annexure-01

GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

CERTIFICATE NO. : **WC-0542**

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: **M/s. Aurore Life Sciences Private Limited**
Plot No. 180/2 & 3, Khazipally (V), Jinnaram (M)
Sangareddy – 502 319 , Telangana, India

List of APIs:

Sr. No.	Active substance (s)	Activity(ies)
1.	Acyclovir USP	Manufacturing & Packing
2.	Aciclovir Ph. Eur.	Manufacturing & Packing

ITEM(S) TWO (02) ONLY

The Written Confirmation remains valid until: Three years from date of issue

Signature

Stamp of the authority and date

Central Drugs Standard Control Organization • Ministry of Health & Family Welfare, Govt. of India •

09 DEC 2022

GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

Annexure-02

CERTIFICATE NO. : WC-0542

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s. Aurore Life Sciences Private Limited
Plot No. 180/2 & 3, Khazipally (V), Jinnaram (M)
Sangareddy – 502 319 , Telangana, India

List of APIs:

Sr. No.	Active substance (s)	Activity(ies)
1.	Molnupiravir IH	Manufacturing & Packing

ITEM(S) ONE (01) ONLY

This certificate is being issued subject to condition that the firm shall obtain NOC from the Competent Authority, on case to case basis, to manufacture the above mentioned active substances for the purpose of export only, as the above mentioned active substances are not approved for manufacture for sale in India.

The Written Confirmation remains valid until: Three years from date of issue

Signature

Central Drugs Standard Control Organization
Ministry of Health & Family Welfare, Govt. of India

Stamp of the authority and date

09 DEC 2022

7-5/2022/EU/WC-0542

Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated: 10 JUN 2024

To,

M/s.Aurore Life Sciences Pvt Ltd,
Plot no. 180/2 & 3, Khazipally (V),
Jinnaram(M), Sangareddy (Dist), Telangana, India

SUB:- Grant of Written Confirmation of M/s. Aurore Life Sciences Pvt Ltd, Plot no. 180/2 & 3, Khazipally (V), Jinnaram(M), Sangareddy (Dist), Telangana, India, as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your online application no. WC/FR/2023/7803 dated 15.12.2023 submitted to DDC(I), CDSCO, Hyderabad Zone and the recommendation received from DDC(I), CDSCO, Hyderabad Zone on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).

2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.

3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.

4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.

5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.

6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.

7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.

8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

9. The manufacturer is required to comply to the provision of GSR 20(E) dated 18.01.2022.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
01	02	09.12.2022	08.12.2025
02	01	09.12.2022	08.12.2025
03	05	10 JUN 2024	08.12.2025

Yours faithfully,

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)

GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

Annexure-03

CERTIFICATE NO. : WC-0542

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s.Aurore Life Sciences Pvt Ltd,
Plot no. 180/2 & 3, Khazipally (V),
Jinnaram(M), Sangareddy (Dist), Telangana, India

List of APIs:

S. No.	Active substance(s)	Activity(ies)
1.	Clozapine IP/USP/Ph.Eur	Manufacturing & Packing
2.	Etoricoxib IH/IP	Manufacturing & Packing
3.	Pinaverium Bromide IH	Manufacturing & Packing
4.	Rebamipide IP/JP	Manufacturing & Packing
5.	Sodium Cromoglicate BP/IP/USP	Manufacturing & Packing

ITEM(S) FIVE (05) ONLY

The Written Confirmation remains valid until: 08.12.2025

Signature

Stamp of the authority and date

10 JUN 2024

7-5/2022/EU/WC-0542

Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated 19 JUN 2025

To

M/s. Aurore Life Sciences Pvt. Ltd.,
Plot No. 180/2 & 3, Khazipally (V),
Jinnaram (M), Sangareddy (Dist.),
Telangana, India

SUB: - Written Confirmation of **M/s. Aurore Life Sciences Pvt. Ltd., Plot No. 180/2 & 3, Khazipally (V), Jinnaram (M), Sangareddy (Dist.), Telangana, India** as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your online application no. WC/FR/2024/8503 submitted to DDC (I), CDSCO Hyderabad Zone office, and the recommendation received from DDC (I), CDSCO Hyderabad Zone on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions: -

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).

2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.

3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.

4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.

5. The Written Confirmation will be withdrawn in the events of non-compliance of Standards.

6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.

7. In the event of any Non-Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.

8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

9. The manufacturer is required to comply with the provisions of GSR 20(E), dated 18.01.2022.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
--	--	09.12.2022	**08.12.2025**
01	02	09.12.2022	**08.12.2025**
02	01	09.12.2022	**08.12.2025**
03	05	10.06.2024	**08.12.2025**
04	06	19 JUN 2025	**08.12.2025**

Yours faithfully,

17/06/25

Ranga Chandrashekar
Joint Drugs Controller (India)

Digitally signed by Ranga Chandrashekar Ranga
संयुक्त औषधि नियंत्रक (भारत) / Joint Drugs Controller(India)
केंद्रीय औषधि मानक नियंत्रण संगठन (मुख्यालय), स्वास्थ्य सेवा महानिदेशालय
C.D.S.C.O(HQ), Dte. General of Health Services
स्वास्थ्य और परिवार कल्याण मंत्रालय / Ministry of Health and Family Welfare
एफ.डी.ए भवन, कोटला रोड, नई दिल्ली-110002 / FDA Bhawan, Kotla Road, New Delhi-110002

GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

Annexure-04
WC-0542

CERTIFICATE NO. :

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: **M/s. Aurore Life Sciences Pvt. Ltd.,**
Plot No. 180/2 & 3, Khazipally (V),
Jinnaram (M), Sangareddy (Dist.),
Telangana, India

List of APIs:

S. No.	Active substance(s)	Activity(ies)
1.	Amlodipine Besylate BP/IP/Ph.Eur.	Manufacturing & Packing
2.	Celecoxib USP/Ph.Eur.	Manufacturing & Packing
3.	Dabigatran Etexilate Mesilate IH	Manufacturing & Packing
4.	Empagliflozin IH	Manufacturing & Packing
5.	Sodium Cromoglicate Ph.Eur.	Manufacturing & Packing
6.	Valaciclovir HCl/Valacyclovir HCl BP/USP	Manufacturing & Packing

ITEM(S) SIX (06) ONLY

The Written Confirmation remains valid until: 08.12.2025

17/06/25

Signature

चन्द्रशेखर रंगा/Chandrashekar Ranga
संयुक्त औषधि नियंत्रक (भारत) / Joint Drugs Controller(India)
केंद्रीय औषधि मानक नियंत्रण संगठन (मुख्यालय), स्वास्थ्य सेवा महानिदेशालय
C.D.S.C.O(HQ), Dte. General of Health Services
स्वास्थ्य और परिवार कल्याण मंत्रालय / Ministry of Health and Family Welfare
एफ.डी.ए भवन, कोटला रोड, नई दिल्ली-110002 / FDA Bhawan, Kotla Road, New Delhi-110002

Stamp of the authority and date

सत्यमेव जयते
Ministry of Health & Family Welfare Govt. of India
19 JUN 2025